Yooyoung Pharmaceutical Co.,Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Seoul Korea, Republic of (1981)
Status: No NME R&D (1981)

Organization Overview

First Clinical Trial
2014
NCT02166593
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Yooyoung Pharmaceutical Co., Ltd. | Yooyoung Pharmaceutical Co.,Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Dyslipidemias (Phase 3)

Esophagitis (Phase 3)

Gastroesophageal Reflux (Phase 3)

Heart Failure (Phase 3)

Neoplasms (Phase 1)

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial APIs: 12